All (n = 112) | BGB-3111-AU-003 (n = 33) | BGB-3111-206 (n = 79) | |
---|---|---|---|
Age | |||
Mean (SD) | 61.55 (9.97) | 69.12 (9.93) | 58.39 (8.16) |
Median | 62 | 70 | 60 |
Sex, male | 86 (77%) | 25 (76%) | 61 (77%) |
BMI, mean (SD) | 24.94 (4.18) | 27.88 (4.82) | 23.72 (3.19) |
ECOG PS, > 1 | 6 (5%) | 3 (9%) | 3 (4%) |
Disease stage | |||
I | 3 (3%) | 2 (6%) | 1 (1%) |
II | 7 (6%) | 0 | 7 (9%) |
III | 14 (13%) | 1 (3%) | 13 (16%) |
IV | 88 (79%) | 30 (91%) | 58 (73%) |
Number of prior lines of therapy, median | 2 | 1 | 2 |
Blastoid variant | 14 (13%) | 2 (6%) | 12 (15%) |
MIPI | |||
High risk | 24 (21%) | 15 (45%) | 9 (11%) |
Intermediate risk | 33 (29%) | 10 (30%) | 23 (29%) |
Low risk | 55 (49%) | 8 (24%) | 47 (59%) |
Bulky | 9 (8%) | 3 (9%) | 6 (8%) |
Extra-nodal | 67 (60%) | 9 (27%) | 58 (73%) |
Bone marrow involvement | 58 (52%) | 21 (64%) | 37 (47%) |